This content is accessible only to 2020 ASCRS Virtual Annual Meeting attendees. If you attended the virtual meeting, please log in with the account associated with your virtual meeting registration. To log in, click the teal "Login" button in the upper right-hand corner of this page.
Presbyopia is an impairment of near vision characterized by gradual loss of the ability of the eyes to focus on nearby objects, and pose burden to patients and healthcare systems. The objective of the present study was to collate and report published evidence on presbyopia burden (prevalence, impact on patient quality of life and associated costs).
A systematic search was conducted in the MEDLINE®, Embase®, and Cochrane Library databases from the time of inception through October 2018. Studies published in the English language reporting the epidemiology and patient and economic burden of presbyopia were included. Overall, 64 studies were included for data extraction and reporting.
Global prevalence of presbyopia is predicted to increase from 1.1 billion in 2015 to 1.8 billion by 2050. In 2010, 89% of adults ≥45 years in the United States (US) suffered from presbyopia. Uncorrected presbyopia increases odds of difficulty in performing near-vision tasks and very demanding near-vision tasks by 2-fold and >8-fold respectively. Uncorrected Presbyopia combined with uncorrected distance vision impairment significantly affects patients’ quality of life. Globally, the potential productivity loss due to uncorrected or under-corrected presbyopia in individuals aged <50 years is estimated to be US $11 billion [0.02% of the global Gross Domestic Product].
Presbyopia poses significant burden to societies, and requires timely and optimal correction to minimize impact on vision quality and productivity.